Previous phase 3, double-blind, randomized trials have demonstrated that combined androgen blockade of bicalutamide 80 mg plus an LH-RH agonist prolonged treatment failure, time to progression, and OS compared to LH-RH monotherapy in patients with locally advanced prostate cancer without metastasis9,14. The gene discussed is GNRH1; the disease is Familial prostate cancer.